Cala announced today that it received FDA clearance for its kIQ Plus next-generation wearable neurostimulation device.

Cala®, the bioelectronic medicine leader, today announced U.S. Food and Drug Administration (FDA) clearance of the Cala kIQ® Plus system, the next-generation of its wearable neurostimulation device ...

Praxis Precision Medicines Inc. PRAX shares are up on Tuesday as the company announced FDA acceptance of its New Drug ...

Praxis, a top biotech stock, surged Tuesday after the FDA assigned a potential approval date for its essential tremor ...

Praxis Precision Medicines shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults. Shares of the ...

FDA assigned PDUFA target action date of January 29, 2027No advisory committee meeting expectedBOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- ...

April is Parkinson's Disease Awareness Month, emphasizing early symptom recognition for timely diagnosis and improved patient ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ulixacaltamide HCl for the treatment of essential tremor in adults. Ulixacaltamid ...

Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026Praxis to ...

Meet Mr Bipin. He is nearing 62. These days, he pauses before signing his name, his hand trembling as he tries to steady the ...

World Parkinson’s Disease Day is often associated with visible symptoms like tremors, but the reality of Parkinson’s disease ...

Learn about rising rates among younger people, and find out the common myths about its symptoms and treatment.